SCHEMBL16113010

SCHEMBL16113010

CCOC(=O)c1ccccc1C1=CCN(C(=O)O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
LMNA P02545 2/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PDK4 Q16654 1/20 0.42
USP2 O75604 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPK10 P53779 1/20 0.41
PTK2B Q14289 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16112803 0.85 PDK4 (0.61) MEN1KMT2APDK4
SCHEMBL4678883 0.82 ALDH1A1 (0.45) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL14636403 0.81 ALDH1A1 (0.43) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL16598132 0.81 ALDH1A1 (0.43) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL22324761 0.79 ALDH1A1 (0.47) TSHRLMNAMAPTALDH1A1MEN1
SCHEMBL3038011 0.79 ALDH1A1 (0.50) LMNAMAPTALDH1A1KDM4ETDP1
SCHEMBL16114190 0.77 ALDH1A1 (0.48) TSHRLMNAMAPTALDH1A1KDM4E
SCHEMBL30707786 0.77 TSHR (0.56) TSHRMAPTALDH1A1KDM4ETDP1
SCHEMBL20993990 0.76 MAPT (0.50) TSHRMAPTALDH1A1MEN1KMT2A
SCHEMBL3321688 0.75 PDE10A (0.54) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301299-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2019-05-28 US disclosed
EP-2970272-A1 GLYCOSIDASE INHIBITORS Merck Patent GmbH (DE) 2016-01-20 EP disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301299-B2 Glycosidase inhibitors GAA, BACE1, GBA3 TSHR 2042/4885LMNA 1238/4885MAPT 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.